본문 바로가기

Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
THORACIC CANCER16(23) · 2025
피인용
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 2.3
ISSN
1759-7706

저자

  1. Song, Yechan제1저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
  2. Choi, Myeong GeunUniv Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
  3. Kim, Yeon JooEulji Univ, Nowon Eulji Med Ctr, Sch Med, Dept Pulmonol, Seoul, South Korea
  4. Lee, Jae CheolUniv Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
  5. Ji, WonjunUniv Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
  6. Oh, In-JaeChonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Med Sch, Dept Internal Med, Hwasun, South Korea
  7. Lee, Sung YongKorea Univ, Guro Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Coll Med, Seoul, South Korea
  8. 윤성훈Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Yangsan, South Korea
  9. Lee, Shin YupKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
  10. Lee, Jeong EunChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol, Daejeon, South Korea
  11. Kim, Eun YoungYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
  12. Kim, Ho YoungHallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Hematol & Oncol, Anyang, South Korea
  13. Choi, Chang-Min교신저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea

초록

Background: We previously reported the short-term real-world effectiveness and safety of first-line atezolizumab combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). This study provides an updated analysis of the effectiveness, prognostic factors, and subsequent treatment patterns in first-line immunochemotherapy. Methods: This prospective multicenter observational study enrolled patients with ES-SCLC, diagnosed at seven university hospitals throughout Korea, between June 2021 and August 2022. Primary outcomes were 1-year overall survival (OS) and progression-free survival (PFS), whereas secondary outcomes included OS, objective response rate, disease control rate, second progression-free survival, and safety, evaluated based on established clinical guidelines. Results: A total of 100 ES-SCLC patients (median age, 69 years) were enrolled, with a median follow-up duration of 26.0 months. The median PFS and OS were 6.2 and 17.1 months, respectively, with a 1-year OS rate of 62.5%. Favorable prognostic factors for OS included partial response (PR) and stable disease (SD) as the best responses (SD: hazard ratio (HR), 0.79; PR: HR, 0.38) and a longer platinum-free interval (HR 0.84). Brain radiotherapy significantly improved OS in patients with brain metastases, whereas thoracic radiotherapy during first-line treatment tended to prolong survival in patients who responded to systemic treatment. Patients receiving second-line treatment after progression presented a significantly longer OS than did those receiving only best supportive care. Conclusion: This study outlined the real-world effectiveness and safety of first-line atezolizumab immunochemotherapy for ES-SCLC patients over an extended follow-up, noting that local treatment and post-progression therapy were associated with improved survival.

키워드

atezolizumabreal-worldsmall cell lung carcinoma

식별자

Scopus EID
2-s2.0-105024698682
WoS UID
001636820100001